Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml

RECOMMENDED

Uro-Oncology

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Lancet Oncol.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J

doi: 10.1016/S1470-2045(19)30415-2.

Uro-Oncology

Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

Prostate.

Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F

doi: 10.1002/pros.23869.

Uro-Oncology

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Prostate.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M

doi: 10.1002/pros.23919.

Uro-Oncology

Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis

J Urol.

Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello F

doi: 10.1097/JU.0000000000001369.

Uro-Oncology

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

BJU Int.

Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker P, Roobol MJ

doi: 10.1111/bju.14944.

Uro-Oncology

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

BJU Int.

Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L

doi: 10.1111/bju.14999.

Uro-Oncology

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

J Urol.

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F

doi: 10.1016/j.juro.2016.09.117.

Uro-Oncology

The Optimal Timing for PSMA PET/CT in Patients with Biochemical Recurrence After Radical Prostatectomy

J Urol.

Luiting HB, van Leeuwen PJ, Remmers S, Donswijk M, Busstra MB, Bakker IL, Brabander T, Stokkel M, van der Poel HG, Roobol MJ

doi: 10.1097/JU.0000000000001012.

Uro-Oncology

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

BJU Int.

Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A

doi: 10.1111/bju.15135.

Related content

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

The Optimal Timing for PSMA PET/CT in Patients with Biochemical Recurrence After Radical Prostatectomy

68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer